Get the Stockscreener App
0.9247
1.04%
0.0095
After Hours:
.94
0.0153
+1.65%
Werewolf Therapeutics Inc stock is traded at $0.9247, with a volume of 444.97K.
It is up +1.04% in the last 24 hours and down -42.21% over the past month.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
See More
Previous Close:
$0.9152
Open:
$0.9806
24h Volume:
444.97K
Relative Volume:
0.55
Market Cap:
$42.29M
Revenue:
$19.94M
Net Income/Loss:
$-37.37M
P/E Ratio:
-0.8891
EPS:
-1.04
Net Cash Flow:
$-33.38M
1W Performance:
-15.17%
1M Performance:
-42.21%
6M Performance:
-17.44%
1Y Performance:
-44.63%
1-Day Range:
$0.90
$0.9999
1-Week Range:
$0.89
$1.09
52-Week Range:
$0.595
$2.38
Werewolf Therapeutics Inc Stock (HOWL) Company Profile
Name
Werewolf Therapeutics Inc
Sector
Industry
Phone
617-952-0555
Address
200 TALCOTT AVENUE, WATERTOWN
Compare HOWL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOWL
Werewolf Therapeutics Inc
|
0.9247 | 44.42M | 19.94M | -37.37M | -33.38M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.03 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.75 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.76 | 61.08B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.59 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.56 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Werewolf Therapeutics Inc Stock (HOWL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-03-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-24-23 | Initiated | Wedbush | Outperform |
| Jun-06-23 | Resumed | Jefferies | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-25-21 | Initiated | Evercore ISI | Outperform |
| May-25-21 | Initiated | H.C. Wainwright | Buy |
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | SVB Leerink | Outperform |
View All
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Werewolf Therapeutics Inc. stock trend forecastEarnings Trend Report & Low Risk Entry Point Tips - newser.com
Werewolf Therapeutics (NASDAQ:HOWL) Price Target Cut to $7.00 by Analysts at Bank of America - Defense World
What MACD signals say about Werewolf Therapeutics Inc.Portfolio Performance Report & High Return Trade Guides - newser.com
B of A Securities Maintains Werewolf Therapeutics (HOWL) Buy Recommendation - Nasdaq
Werewolf therapeutics (HOWL) sees $200k+ in sales by MPM related entities - Investing.com Nigeria
Evnin Luke sells Werewolf Therapeutics (HOWL) shares worth $128k By Investing.com - Investing.com South Africa
Mpm Bioventures sells Werewolf Therapeutics (HOWL) stock for $200,665 By Investing.com - Investing.com Nigeria
Evnin Luke sells Werewolf Therapeutics (HOWL) shares worth $128k - Investing.com
Mpm Bioventures sells Werewolf Therapeutics (HOWL) stock for $200,665 - Investing.com
Views of Wall Street’s Leading Experts on Werewolf Therapeutics Inc - Setenews
Will Werewolf Therapeutics Inc. price bounce be sustainableRisk Management & Free Community Consensus Stock Picks - newser.com
How Werewolf Therapeutics Inc. stock performs after earningsSwing Trade & Daily Price Action Insights - newser.com
Why Werewolf Therapeutics Inc. stock is rated strong buyMarket Sentiment Report & Trade Opportunity Analysis Reports - Fundação Cultural do Pará
Werewolf Therapeutics Inc. stock trendline breakdown2025 Price Momentum & Consistent Income Trade Ideas - newser.com
Will Werewolf Therapeutics Inc. stock recover faster than marketFed Meeting & Low Drawdown Trading Techniques - newser.com
Advanced analytics toolkit walkthrough for Werewolf Therapeutics Inc.Market Growth Summary & Precise Swing Trade Alerts - newser.com
Evnin Luke, director at Werewolf Therapeutics, sells $154k in HOWL By Investing.com - Investing.com South Africa
Werewolf Therapeutics (HOWL) 10% owners sell $241k in stock By Investing.com - Investing.com Nigeria
Evnin Luke, director at Werewolf Therapeutics, sells $154k in HOWL - Investing.com Nigeria
Mpm Bioventures sells Werewolf Therapeutics (HOWL) shares for $241k By Investing.com - Investing.com Nigeria
Werewolf Therapeutics (HOWL) 10% owners sell $241k in stock - Investing.com
Mpm Bioventures sells Werewolf Therapeutics (HOWL) shares for $241k - Investing.com
Analyzing recovery setups for Werewolf Therapeutics Inc. investorsPortfolio Profit Report & Stock Market Timing Techniques - newser.com
Citizens reiterates Market Outperform rating on Werewolf Therapeutics stock By Investing.com - Investing.com Nigeria
Visual trend scoring systems applied to Werewolf Therapeutics Inc.Market Risk Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Citizens reiterates Market Outperform rating on Werewolf Therapeutics stock - Investing.com
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Receives $8.00 Consensus Price Target from Brokerages - Defense World
Werewolf Therapeutics Inc (HOWL) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Werewolf Therapeutics Inc Stock (HOWL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):